OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0000737207

Adhera Therapeutics, Inc.

Adhera Therapeutics, Inc. (CIK 0000737207, EIN 11-2658569) reported revenue of $252,000 for FY2019 (2019-01-01 to 2019-12-31) and net income of -$2.11 million (-$2,114,000) for FY2022 (2022-01-01 to 2022-12-31), as filed in its 10-K filed 2021-04-07 (accession 0001493152-21-008190) and its 10-K filed 2023-03-31 (accession 0001493152-23-010160).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0000737207
EIN11-2658569
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_4m9bp3yync53rv71jzwcm06bgv
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$252,000FY20192019-01-01 to 2019-12-3110-K2021-04-070001493152-21-008190RevenueFromContractWithCustomerExcludingAssessedTax
Net income-$2,114,000FY20222022-01-01 to 2022-12-3110-K2023-03-310001493152-23-010160NetIncomeLoss
Total assets$79,000FY2022as of 2022-12-3110-K2023-03-310001493152-23-010160Assets
Total liabilities$22,265,000FY2022as of 2022-12-3110-K2023-03-310001493152-23-010160Liabilities
Stockholders' equity-$22,186,000FY2022as of 2022-12-3110-K2023-03-310001493152-23-010160StockholdersEquity
Operating cash flow-$1,415,000FY20222022-01-01 to 2022-12-3110-K2023-03-310001493152-23-010160NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$0.65 per shareFY20212021-01-01 to 2021-12-3110-K2022-04-150001493152-22-010064EarningsPerShareBasicAndDiluted
Shares outstanding3,178,738 sharesFY2022as of 2023-03-3110-K2023-03-310001493152-23-010160EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2013-2022, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20192019-01-01 to 2019-12-31$252,00010-K2021-04-070001493152-21-008190
RevenueFY20182018-01-01 to 2018-12-31$76,00010-K2020-04-140000737207-20-000006
Net incomeFY20222022-01-01 to 2022-12-31-$2,114,00010-K2023-03-310001493152-23-010160
Net incomeFY20212021-01-01 to 2021-12-31-$6,351,00010-K2023-03-310001493152-23-010160
Net incomeFY20202020-01-01 to 2020-12-31-$3,766,00010-K2022-04-150001493152-22-010064
Net incomeFY20192019-01-01 to 2019-12-31-$11,978,00010-K2021-04-070001493152-21-008190
Net incomeFY20182018-01-01 to 2018-12-31-$16,755,00010-K2020-04-140000737207-20-000006
Net incomeFY20172017-01-01 to 2017-12-31-$6,219,34810-K2019-04-160001493152-19-005482
Net incomeFY20162016-01-01 to 2016-12-31-$837,14310-K2018-04-170001493152-18-005372
Net incomeFY20152015-01-01 to 2015-12-31-$1,108,56410-K2017-03-310001493152-17-003272
Net incomeFY20142014-01-01 to 2014-12-31-$6,477,00010-K2016-03-300001571049-16-013489
Net incomeFY20132013-01-01 to 2013-12-31-$1,571,00010-K2015-02-180001571049-15-001227
  • Revenue for FY2018 was restated: first reported as $76,186 (accession 0001493152-19-005482, filed 2019-04-16).
  • Net income for FY2018 was restated: first reported as -$16,754,957 (accession 0001493152-19-005482, filed 2019-04-16).
  • Net income for FY2015 was restated: first reported as $3,337,000 (accession 0001571049-16-013489, filed 2016-03-30).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2023-11-202023-09-300001493152-23-042138form10-q.htm
10-Q2023-08-212023-06-300001493152-23-029594form10-q.htm
10-Q2023-05-222023-03-310001493152-23-018516form10-q.htm
10-K/A2023-05-022022-12-310001493152-23-015188form10-ka.htm
10-K2023-03-312022-12-310001493152-23-010160form10-k.htm
10-Q2022-11-142022-09-300001493152-22-031940form10-q.htm
10-Q2022-08-152022-06-300001493152-22-022832form10-q.htm
10-Q2022-05-162022-03-310001493152-22-013775form10-q.htm
10-K/A2022-04-292021-12-310001493152-22-011601form10ka.htm
10-K2022-04-152021-12-310001493152-22-010064form10-k.htm
10-Q2021-11-222021-09-300001493152-21-029537form10-q.htm
10-Q2021-08-232021-06-300001493152-21-020974form10-q.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0000737207published by the sourcedata.sec.gov/submissions/CIK0000737207.json2026-10-21
Employer Identification Number (EIN) · US-EIN11-2658569published by the sourcedata.sec.gov/submissions/CIK0000737207.json2026-10-21

Former names

NameFromTo
Marina Biotech, Inc.2010-06-282018-10-09
MDRNA, Inc.2008-06-102010-07-21
NASTECH PHARMACEUTICAL CO INC1995-10-162008-06-09

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0000737207.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0000737207.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000737207" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000737207/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000737207/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"737207"}

On SEC EDGAR

About this data